AlphaTON Capital Corp (NASDAQ: ATON)

Portage Biotech Inc., a company that trades under the symbol PTB on the TSX Venture Exchange, is a clinical-stage immune-oncology company operating in the biotechnology industry. The company's main business activities involve the development and commercialization of immuno-oncology therapeutic candidates, with a focus on adenosine receptor antagonists that target the adenosine pathway to modulate the immune response and enhance cancer treatment. Portage Biotech's operations span across various countries, including Canada, the United States, and the Netherlands.

The company generates revenue primarily through the development of its immuno-oncology therapeutic candidates. Its primary products include adenosine receptor antagonists, which are designed to target the adenosine pathway and improve the response to cancer treatment. Portage Biotech's pipeline portfolio includes four adenosine antagonists, which are expected to provide a comprehensive exploration of how targeting the adenosine pathway could potentially improve response in multiple cancer and non-cancer indications.

Portage Biotech operates in a highly competitive industry, with numerous biotechnology companies developing immuno-oncology therapies. However, the company has several competitive advantages, including its diversified pipeline of immuno-oncology therapeutic candidates and programs, its focus on translational medicine and therapeutic candidates with single agent activity, and its ability to leverage its internal development capabilities and external business development opportunities.

Portage Biotech's customers include patients with invasive cancers, as well as healthcare providers and researchers in the field of immuno-oncology. The company's products are designed to improve long-term treatment response and quality of life in patients with invasive cancers, and its pipeline portfolio is expected to provide a comprehensive exploration of how targeting the adenosine pathway could potentially improve response in multiple cancer and non-cancer indications.

The company's adenosine receptor antagonist platform is a critical mechanism of cancer immune evasion, with high levels of immunosuppressive adenosine within the tumor microenvironment. Research suggests that the tumor microenvironment has significantly elevated concentrations of extracellular adenosine, which engages with adenosine receptors type 2A and type 2B, triggering a dampening effect on the immune response and suppressing effector cell function.

Portage Biotech's business model is designed to facilitate flexibility in financing and ease of partnering, licensing, and merger/acquisition of individual assets and or technology platforms. The company's intellectual property for each platform is held in separate private entities. The company's employees and consultants work across the pipeline of assets, and the company believes that this can enhance operational efficiency, maintain an optimal cost structure, attract leading collaborators, and promote asset flexibility.

In addition, Portage Biotech has collaborations with experts in the products areas for which it provides access to its compounds and collaborates on studies. The company is also exploring strategic alternatives, which may include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings, both in and out of court, a company wind down, further financing efforts, or other strategic action.